Bank Of America Corp Ngm Biopharmaceuticals Inc Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.17 - $1.92 $36,551 - $59,982	-31,241 Reduced 54.85%	25,721 $40,000
Q4 2023 Feb 14, 2024	SELL	$0.6 - $1.31 $31,734 - $69,287	-52,891 Reduced 48.15%	56,962 $48,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $62,993 - $116,951	25,817 Added 30.72%	109,853 $284,000
Q1 2023 May 12, 2023	BUY	$3.72 - $5.4 $109,847 - $159,456	29,529 Added 54.17%	84,036 $342,000
Q4 2022 Feb 10, 2023	BUY	$3.41 - $12.93 $46,965 - $178,084	13,773 Added 33.81%	54,507 $273,000
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $1.26 Million - $1.77 Million	-100,148 Reduced 71.09%	40,734 $533,000
Q2 2022 Aug 12, 2022	BUY	$10.58 - $17.5 $1.06 Million - $1.75 Million	100,100 Added 245.45%	140,882 $1.81 Million
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $71,867 - $96,794	-5,204 Reduced 11.32%	40,782 $622,000
Q4 2021 Feb 08, 2022	BUY	$17.26 - $22.02 $223,706 - $285,401	12,961 Added 39.25%	45,986 $814,000
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $408,702 - $531,211	20,283 Added 159.18%	33,025 $695,000
Q2 2021 Sep 13, 2021	BUY	$15.06 - $30.03 $191,894 - $382,642	12,742 New	12,742 $251,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.